Evidence map›Paper›PMID 28580437›Full record

ArticlePathogens & immunity2017

Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection.

Robert M Paris, Lucimar G Milagres, Eirini Moysi, Jason F Okulicz, Brian K Agan, Anu Ganesan, Constantinos Petrovas, Richard A Koup

Open access · diamondAbstract read
In one paragraph

Article in Pathogens & immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Robert M ParisUS Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland.
Lucimar G MilagresImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland.
Eirini MoysiTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland.
Jason F OkuliczInfectious Diseases Service and HIV Medical Evaluation Unit, San Antonio Military Medical Center, San Antonio, Texas.
Brian K AganInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Anu GanesanInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Constantinos PetrovasTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland.
Richard A KoupImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland.
National Institutes of Health · USHenry M. Jackson Foundation · USBrooke Army Medical Center · US

Funding

Tfh and B cells in HIV/SIV pathogenesis and vaccinationZIAAI005015 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$24.1M
HIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7M
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

backgroundWhy HIV-infected individuals have poor responses to standard dose and schedule hepatitis B virus immunization is not well understood.

methodsWe compared the serologic and cellular immune profiles of treated HIV-infected individuals with similar durations of infection and preserved CD4 counts (> 350 cells/microliter) by hepatitis B vaccine (HBV) response before and after vaccination.

resultsSimilar levels of immune activation and plasma cytokine profile were found between non-responders and responders. The baseline plasma levels of CXCL-13, a surrogate of germinal center reactivity, were significantly lower in HBV responders compared to HBV non-responders and were a predictor of both vaccine response and titer. Furthermore, response to HBV vaccination was associated with a significantly higher frequency of circulating IgG

conclusionsTaken together, our data suggest that preserved Th1 responses are associated with hepatitis B vaccine response in treated HIV infection.

Indexed as

AIDSantibodieshepatitis B vaccineHuman immunodeficiency virusT cell

Identifiers

PMID28580437
PMCPMC5450971
OpenAlexW2595594390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.